German drugmaker Boehringer Ingelheim has its first regulatory ... but would not diclose the list price for the drug, saying simply that the company is "working closely with insurance companies ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

Boehringer Ingelheim has taken an option on ... which are the target of around a third of all marketed drugs, and Boehringer adds to a growing list of partners that also includes AbbVie ...

With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies ...

The partnership covers drugs currently under early-stage clinical development by Boehringer Ingelheim ... on the Forbes Real-Time Billionaires List today. Besides son Eric, Sino Biopharmaceutical ...

“If you have to pay based on the list price ... a commercial official at drugmaker Boehringer Ingelheim. In July, the company ...

Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim scientists, have developed a breakthrough small-molecule drug ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

When the Inflation Reduction Act was signed into law in 2022, it authorized a number of initiatives aimed at reducing the ...

Boehringer Ingelheim GmbH is open to more dealmaking to build its obesity portfolio even as it stays “laser-focused” on bringing its first weight-loss drug to market, its global head of therap ...

Patient centricity in artificial intelligence in drug development are two of the ... Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin.